Malignancy rates in patients with moderate to severe psoriasis during treatment with risankizumab: Analysis of pooled clinical trial data

Background: Risankizumab (RZB) is a humanized IgG1 monoclonal antibody that binds to the p19 subunit and selectively inhibits interleukin-23, a cytokine that plays a key role in the development and maintenance of psoriatic lesionsObjective: To report the short- and longer-term rates of malignancies in patients with moderate to severe psoriasis treated with RZB.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research